{
    "title": "Novartis' Sandoz wagers its standalone future on biosimilar success",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12172659/Novartis-sees-Sandoz-adding-3-bln-net-sales-five-years.html",
    "date": "2023-06-08",
    "keywords": [
        "sandoz",
        "market",
        "company",
        "drug",
        "year",
        "grover",
        "novartis",
        "bond",
        "interest",
        "range",
        "biosimilar",
        "london",
        "june",
        "division",
        "arthritis",
        "cancer",
        "future",
        "standalone",
        "capital",
        "day",
        "york",
        "case",
        "firepower",
        "pipeline",
        "environment",
        "review",
        "period",
        "underperformance",
        "pricing",
        "sector",
        "decision",
        "business",
        "uptake",
        "revenue",
        "biologic",
        "living",
        "fifth",
        "percentage",
        "cfo",
        "colin",
        "core",
        "margin",
        "depreciation",
        "amortization",
        "ebidta",
        "midterm",
        "start",
        "journey",
        "likelihood",
        "inflation",
        "cooling",
        "highmargin",
        "expansion",
        "launch",
        "humira",
        "blockbuster",
        "patent",
        "protection",
        "europe",
        "decade",
        "accounting",
        "mckinsey",
        "analysis",
        "space",
        "amgen",
        "half",
        "reporting",
        "editing",
        "himani",
        "sarkar",
        "mark",
        "potter",
        "lisa",
        "shumaker"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}